Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Hanley

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Cytotherapy|November 9, 2023
Review of flow cytometry as a tool for cell and gene therapyChristopher A Lazarski, Patrick J Hanley
Cytotherapy|March 21, 2019
Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapiesBen Weil, Patrick J Hanley, Mark Lowdell
Cytotherapy|November 23, 2021
ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy productsAlexey Bersenev, Michael P Gustafson, Patrick J Hanley
Cytotherapy|November 10, 2021
Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experiencePatrick J Hanley, Alexey Bersenev, Michael P Gustafson
Cytotherapy|January 21, 2014
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of careFrancesco Saglio, Patrick J Hanley, Catherine M Bollard
Frontiers in Pediatrics|February 14, 2022
Editorial: Advances in Pediatric Hematopoietic Cell Therapies and TransplantationEmmanuel Katsanis, Patrick J Hanley, Richard J Simpson
Cytotherapy|June 9, 2026
Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?Mostafa Seblani, Serge Yaacoub, Patrick J Hanley, et al.
Current Hematologic Malignancy Reports|August 2, 2017
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma ImmunotherapyAndrew D Fesnak, Patrick J Hanley, Bruce L Levine
Cytotherapy|January 30, 2015
Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodPatrick J Hanley, Catherine M Bollard, Claudio G Brunstein
Transfusion|August 31, 2019
The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing developmentAlyssa Fatic, Nan Zhang, Michael D Keller, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Cytotherapy|November 9, 2023
Review of flow cytometry as a tool for cell and gene therapyChristopher A Lazarski, Patrick J Hanley
Cytotherapy|March 21, 2019
Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapiesBen Weil, Patrick J Hanley, Mark Lowdell
Cytotherapy|November 23, 2021
ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy productsAlexey Bersenev, Michael P Gustafson, Patrick J Hanley
Cytotherapy|November 10, 2021
Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experiencePatrick J Hanley, Alexey Bersenev, Michael P Gustafson
Cytotherapy|January 21, 2014
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of careFrancesco Saglio, Patrick J Hanley, Catherine M Bollard
Frontiers in Pediatrics|February 14, 2022
Editorial: Advances in Pediatric Hematopoietic Cell Therapies and TransplantationEmmanuel Katsanis, Patrick J Hanley, Richard J Simpson
Cytotherapy|June 9, 2026
Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?Mostafa Seblani, Serge Yaacoub, Patrick J Hanley, et al.
Current Hematologic Malignancy Reports|August 2, 2017
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma ImmunotherapyAndrew D Fesnak, Patrick J Hanley, Bruce L Levine
Cytotherapy|January 30, 2015
Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodPatrick J Hanley, Catherine M Bollard, Claudio G Brunstein
Transfusion|August 31, 2019
The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing developmentAlyssa Fatic, Nan Zhang, Michael D Keller, et al.
Pageof 10